Bland P, Saville H, Wai PT, Curnow L, Nieminuszczy J, Ravindran N, Barker HE, Wright J, Yu L, Mavrommati I, Peck B, Gazinska P, Pemberton HN, Gulati A, Guppy N, Roxanis I, Pratt G, Oldreive C, Stankovic T, Barlow S, Kalirai H, Coupland SE, Broderick R, Alsafadi S, Houy A, Stern M-H, Pettit S, Choudhary JS, Haider S and Niedzwiedz W (2023). Abstract B020: SF3B1  hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response. American Association For Cancer Research (Aacr)  Molecular Cancer Therapeutics  vol. 22, (12_Supplement) b020-b020. 10.1158/1535-7163.targ-23-b020

Bland P, Saville H, Wai PT, Curnow L, Muirhead G, Nieminuszczy J, Ravindran N, John MB, Hedayat S, Barker HE, Wright J, Yu L, Mavrommati I, Read A, Peck B, Allen M, Gazinska P, Pemberton HN, Gulati A, Nash S, Noor F, Guppy N, Roxanis I, Pratt G, Oldreive C, Stankovic T, Barlow S, Kalirai H, Coupland SE and Broderick R (2023). SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response. Springer Nature  Nature Genetics  vol. 55, (8) 1311-1323. 10.1038/s41588-023-01460-5

Bland P, Saville H, Read A, Wai P, Muirhead G, Curnow L, Nieminuszczy J, Ravindran N, John M, Hedayat S, Barker H, Wright J, Yu L, Mavrommati I, Peck B, Allen M, Gazinska P, Pemberton H, Gulati A, Nash S, Noor F, Guppy N, Roxanis I, Barlow S, Kalirai H, Coupland S, Broderick R, Alsafadi S, Houy A and Stern M-H (2023). Abstract P6-10-05: Mutations in the RNA Splicing Factor SF3B1 drive endocrine therapy resistance and confer a targetable replication stress response defect through PARP inhibition. American Association For Cancer Research (Aacr)  Cancer Research  vol. 83, (5_Supplement) 10.1158/1538-7445.sabcs22-p6-10-05

Heydt Q, Xintaropoulou C, Clear A, Austin M, Pislariu I, Miraki-Moud F, Cutillas P, Korfi K, Calaminici M, Cawthorn W, Suchacki K, Nagano A, Gribben JG, Smith M, Cavenagh JD, Oakervee H, Castleton A, Taussig D, Peck B, Wilczynska A, McNaughton L, Bonnet D, Mardakheh F and Wrench B (2021). Adipocytes disrupt the translational programme of acute lymphoblastic leukaemia to favour tumour survival and persistence. Nature Research (Part of Springer Nature)  Nature Communications  10.1038/s41467-021-25540-4

Peck B, Bland P, Mavrommati I, Muirhead G, Cottom H, Wai PT, Maguire SL, Barker HE, Morrison E, Kriplani D, Yu L, Gibson A, Falgari G, Brennan K, Farnie G, Buus R, Marlow R, Novo D, Knight E, Guppy N, Kolarevic D, Susnjar S, Milijic NM, Naidoo K, Gazinska P, Roxanis I, Pancholi S, Martin L-A, Holgersen EM and Cheang MCU (2021). 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. American Association For Cancer Research (Aacr)  Cancer Research  vol. 81, (4) 847-859. 10.1158/0008-5472.can-20-1822

Kapara A, Vannini A and Peck B (2020). A micronutrient with major effects on cancer cell viability. Nature Research  Nature Metabolism  10.1038/s42255-020-0244-3

Peck B and Schulze A (2019). Lipid Metabolism at the Nexus of Diet and Tumor Microenvironment. Elsevier  Trends in Cancer  vol. 5, (11) 693-703. 10.1016/j.trecan.2019.09.007

Jones DT, Valli A, Haider S, Zhang Q, Smethurst EA, Schug ZT, Peck B, Aboagye EO, Critchlow SE, Schulze A, Gottlieb E, Wakelam MJO and Harris AL (2018). 3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers. American Association For Cancer Research  Molecular Cancer Therapeutics  vol. 18, (2) 376-388. 10.1158/1535-7163.MCT-17-0857

Peck B, Bland PJ, Wai PT, Cottom H, Maguire SL, Morrison E, Barker HE, Kriplani D, Marlow R, Naidoo K, Muirhead G, Haider S, Daley F, Wallberg F, Tutt AN and Natrajan RC (2018). Abstract 788: Modeling tumor microenvironmental heterogeneity identifies CREBBP as a novel tumor suppressor in breast cancer. American Association For Cancer Research (Aacr)  Cancer Research  vol. 78, (13_Supplement) 788-788. 10.1158/1538-7445.am2018-788

Miess H, Dankworth B, Gouw AM, Rosenfeldt M, Schmitz W, Jiang M, Saunders B, Howell M, Downward J, Felsher DW, Peck B and Schulze A (2018). The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Springer Nature  Oncogene  vol. 37, (40) 5435-5450. 10.1038/s41388-018-0315-z

Khalique S, Williamson CT, Pemberton H, Wai PT, Menon M, Brough R, Leonidou A, Peck B, Banerjee S, Natrajan RC and Lord CJ (2017). Abstract NTOC-093: SYNTHETIC LETHAL APPROACHES TO TARGET ARID1A DEFICIENT OVARIAN CANCERS. American Association For Cancer Research (Aacr)  Clinical Cancer Research  vol. 23, (11_Supplement) 10.1158/1557-3265.ovcasymp16-ntoc-093

Leonidou A, Peck B and Natrajan R (2017). Identification and Validation of Driver Kinases from Next-Generation Sequencing Data. Springer Nature  10.1007/978-1-4939-7154-1_12

Morrison E, Wai P, Leonidou A, Bland P, Khalique S, Farnie G, Daley F, Peck B and Natrajan R (2016). Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures. Myjove Corporation  Journal of Visualized Experiments  (118) 10.3791/54738

Maguire SL, Peck B, Wai PT, Campbell J, Barker H, Gulati A, Daley F, Vyse S, Huang P, Lord CJ, Farnie G, Brennan K and Natrajan R (2016). Three‐dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. Wiley  The Journal of Pathology  vol. 240, (3) 315-328. 10.1002/path.4778

Leonidou A, Maguire SL, Wai PT, Huang P, Peck B and Natrajan RC (2016). 130 Functional assessment of low-frequency mutations in breast cancer. Elsevier  European Journal of Cancer  vol. 61, 10.1016/s0959-8049(16)61048-1

Peck B, Maguire S, Morrison E, Wai P and Natrajan R (2016). 362 Modelling the tumour microenvironment and employing functional genomics identifies CREBBP as a novel tumour suppressor in triple negative breast cancers. Elsevier  European Journal of Cancer  vol. 61, s73-s74. 10.1016/s0959-8049(16)61256-x

Peck B, Schug ZT, Zhang Q, Dankworth B, Jones DT, Smethurst E, Patel R, Mason S, Jiang M, Saunders R, Howell M, Mitter R, Spencer-Dene B, Stamp G, McGarry L, James D, Shanks E, Aboagye EO, Critchlow SE, Leung HY, Harris AL, Wakelam MJO, Gottlieb E and Schulze A (2016). Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Springer Nature  Cancer & Metabolism  vol. 4, (1) 10.1186/s40170-016-0146-8

Peck B and Schulze A (2016). Lipid desaturation – the next step in targeting lipogenesis in cancer? Wiley  The Febs Journal  vol. 283, (15) 2767-2778. 10.1111/febs.13681

Peck B, Maguire S, Morrison E, Wai P and Natrajan R (2016). Abstract PR06: Modeling the tumor microenvironment to identify novel loss of function mutations in breast cancer progression. American Association For Cancer Research (Aacr)  Molecular Cancer Research  vol. 14, (2_Supplement) pr06-pr06. 10.1158/1557-3125.advbc15-pr06

Lewis CA, Brault C, Peck B, Bensaad K, Griffiths B, Mitter R, Chakravarty P, East P, Dankworth B, Alibhai D, Harris AL and Schulze A (2015). SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. Springer Nature  Oncogene  vol. 34, (40) 5128-5140. 10.1038/onc.2014.439

Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K, McGarry L, James D, Shanks E, Kalna G, Saunders RE, Jiang M, Howell M, Lassailly F, Thin MZ, Spencer-Dene B, Stamp G, van den Broek NJF, Mackay G, Bulusu V, Kamphorst JJ, Tardito S, Strachan D, Harris AL, Aboagye EO and Critchlow SE (2015). Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress. Elsevier  Cancer Cell  vol. 27, (1) 57-71. 10.1016/j.ccell.2014.12.002

Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, Pinnick KE, Wigfield S, Buffa FM, Li J-L, Zhang Q, Wakelam MJO, Karpe F, Schulze A and Harris AL (2014). Fatty Acid Uptake and Lipid Storage Induced by HIF-1α Contribute to Cell Growth and Survival after Hypoxia-Reoxygenation. Elsevier  Cell Reports  vol. 9, (1) 349-365. 10.1016/j.celrep.2014.08.056

Schug Z, Peck B, Jones D, Zhang Q, Alam I, Witney T, Smethurst E, Grosskurth S, Harris A, Critchlow S, Aboagye E, Wakelam M, Schulze A and Gottlieb E (2014). Acetyl-coA synthetase 2 promotes acetate utilization and maintains cell growth under metabolic stress. Springer Nature  Cancer & Metabolism  vol. 2, (Suppl 1) 10.1186/2049-3002-2-s1-o9

Peck B and Schulze A (2014). Cholesteryl Esters: Fueling the Fury of Prostate Cancer. Elsevier  Cell Metabolism  vol. 19, (3) 350-352. 10.1016/j.cmet.2014.02.012

Baenke F, Peck B, Miess H and Schulze A (2013). Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. The Company of Biologists  Disease Models & Mechanisms  vol. 6, (6) 1353-1363. 10.1242/dmm.011338

Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, Konisti S, Peck B, Miess H, East P, Wakelam M, Harris AL and Schulze A (2013). Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Springer Nature  Cancer & Metabolism  vol. 1, (1) 10.1186/2049-3002-1-3

Peck B, Ferber EC and Schulze A (2013). Antagonism between FOXO and MYC Regulates Cellular Powerhouse. Frontiers  Frontiers in Oncology  vol. 3, 10.3389/fonc.2013.00096

Ferber EC, Peck B, Delpuech O, Bell GP, East P and Schulze A (2011). FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Springer Nature  Cell Death & Differentiation  vol. 19, (6) 968-979. 10.1038/cdd.2011.179

Peck B and Schulze A (2011). A role for the cancer-associated miR-106b~25 cluster in neuronal stem cells. Impact Journals, Llc  Aging  vol. 3, (4) 329-331. 10.18632/aging.100302

Peck B, Chen C-Y, Ho K-K, Di Fruscia P, Myatt SS, Coombes RC, Fuchter MJ, Hsiao C-D and Lam EW-F (2010). SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2. American Association For Cancer Research (Aacr)  Molecular Cancer Therapeutics  vol. 9, (4) 844-855. 10.1158/1535-7163.mct-09-0971

Kwok JM-M, Peck B, Monteiro LJ, Schwenen HDC, Millour J, Coombes RC, Myatt SS and Lam EW-F (2010). FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells. American Association For Cancer Research (Aacr)  Molecular Cancer Research  vol. 8, (1) 24-34. 10.1158/1541-7786.mcr-09-0432

Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, Palmieri C, Peston D, Shousha S, Yu Q, Sicinski P, Coombes RC and Lam EW-F (2009). FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Spandidos Publications  International Journal of Oncology  vol. 35, (1) 57-68. 10.3892/ijo_00000313

McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, Krol J, Kwok JM-M, Polychronis A, Coombes RC and Lam EW-F (2009). Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. American Association For Cancer Research (Aacr)  Molecular Cancer Therapeutics  vol. 8, (3) 582-591. 10.1158/1535-7163.mct-08-0805